Notably, the opposite effects of DPP-4i, that promote sympathetic activation and vasoconstriction, cannot be ignored when combined with anti-hypertensive drugs
Thus far, approximately 40 companies worldwide, including Codiak Biosciences, Evox Therapeutics, Tavec Pharmaceuticals, Carmine Therapeutics, Anjarium, and Micromedmark Biotech, have developed exosome-based therapies, which are expected to provide cost-effective and more accurate targeted therapies in the clinic ( However, challenges, such as large-scale production, purity, and batch homogeneity of exosomes, still limit their clinical application
There is no ramp-up and no dose adjustment mid-cycle
This trend is likely to encourage more healthcare providers to prescribe these therapies, thereby expanding the market
However, since NAC suffers from poor oral bioavailability, large doses are required to provide a therapeutic benefit [13]